4-bromo-N,N-dimethylquinolin-2-amine | 260972-96-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 4-bromo-N,N-dimethylquinolin-2-amine
• 英文别名: 4-Bromo-N,N-dimethyl-2-quinolineamine；4-bromo-2-dimethylaminoquinoline
• CAS: 260972-96-1
• 化学式: C₁₁H₁₁BrN₂
• 分子量: 251.126
• InChiKey: GXDQKUMHPDKGHM-UHFFFAOYSA-N

物化性质

• 沸点：
  378.9±27.0 °C(Predicted)
• 密度：
  1.468±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  16.1
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  2,4-二溴喹啉 以 水 、 二甲胺 为溶剂， 生成 4-bromo-N,N-dimethylquinolin-2-amine
  参考文献：
  名称：

  Spiro-cyclic beta-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-alpha converting enzyme (TACE)

  摘要：

  本申请描述了新颖的式I的螺环式&bgr;-氨基酸衍生物或其药用盐形式，其中环B是3-13成员碳环或杂环，环C形成3-11成员的螺环碳环或螺环杂环在环B上，并且其他变量在本规范中定义，这些衍生物可用作基质金属蛋白酶（MMP）、TNF-&agr;转化酶（TACE）和/或聚集素酶抑制剂。

  公开号：

  US20030087882A1

文献信息

• Cyclic hydroxamic acids as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme (TACE)
  申请人：——

  公开号：US20030139388A1

  公开（公告）日：2003-07-24

  The present application describes novel cyclic hydroxamic acids of formula I: 1 or pharmaceutically acceptable salt forms thereof, wherein ring B is a 5-7 membered cyclic system containing from 0-2 heteroatoms selected from O, N, NR 1 , and S(O) p , and 0-1 carbonyl groups and the other variables are defined in the present specification, which are useful as inhibitors of matrix metalloproteinases (MMP), TNF-&agr; converting enzyme (TACE), aggrecanase or a combination thereof, pharmaceutical compositions containing the same, and methods of using the same.

  本申请描述了新型的公式I:1的环式羟羧酸，或其药用盐形式，其中环B是一个包含0-2个来自O、N、NR1和S(O)p的杂原子以及0-1个羰基的5-7元环系统，其他变量在本说明书中有定义，这些化合物可作为基质金属蛋白酶（MMP）、TNF-α转化酶（TACE）、聚集素酶或其组合的抑制剂，包含这些化合物的药物组合物，以及使用这些化合物的方法。
• Nucleophilic Aromatic Substitution Reactions in Water Enabled by Micellar Catalysis
  作者：Nicholas A. Isley、Roscoe T. H. Linstadt、Sean M. Kelly、Fabrice Gallou、Bruce H. Lipshutz

  DOI：10.1021/acs.orglett.5b02240

  日期：2015.10.2

  DMSO, DMAc, and NMP in nucleophilic aromatic substitution reactions (SNAr), a simple and environmentally friendly alternative is reported. Use of a “benign-by-design” nonionic surfactant, TPGS-750-M, in water enables nitrogen, oxygen, and sulfur nucleophiles to participate in SNAr reactions. Aromatic and heteroaromatic substrates readily participate in this micellar catalysis, which takes place at or

  鉴于对偶极的巨大依赖性，非质子溶剂如DMF，DMSO，DMAC，和NMP中的亲核芳族取代反应（S Ñ报道的Ar），一个简单的和环境友好的替代品。在水中使用“良性设计”非离子表面活性剂TPGS-750-M可使氮，氧和硫亲核试剂参与S N Ar反应。芳族和杂芳族底物容易参与这种胶束催化，该胶束催化在环境温度或环境温度附近发生。
• 4-Quinolinemethanol derivatives as purine receptor antagonists (1)
  申请人：Vernalis Research Limited

  公开号：US06583156B1

  公开（公告）日：2003-06-24

  Use a compound of formula (I) wherein: R1 is hydrogen or alkyl; R2 and R3 are independently selected from hydrogen, alkyl, aryl and heterocyclyle or together may form a ring or R1 and R2 or R3 together may form an oxygen-containing, optionally fused ring pharmaceutically acceptable salts or prodrugs thereof, with the proviso that where R1 and R4 to R9 are hydrogen, R2 or R3 is not 3-methoxy-4-benzyloxyphenyl or 2-dimethylaminoethoxymethyl, in the manufacture of a medicament for the treatment or prevention of a disorder in which the blocking of purine receptors, particularly adenosine receptors and more particularly A2A receptors, may be beneficial. Said disorders are neurodegenerative disorders or movement disorders selected from Parkinson's disease or progressive supernuclear palsy, Huntington's disease, multiple system atrophy, corticobasal degeneration, Wilson's disease, Hallerrorden-Spatz disease, progressive pallidal atrophy, Dopa-responsive dystonia-Parkinsonism, spasticity, Alzheimer's disease or other disorders of the basal ganglia which result in dyskinesias.

  使用式(I)的复合物，其中：R1是氢或烷基；R2和R3独立选择自氢、烷基、芳香基和杂环基，或者一起可以形成环，或者R1和R2或R3一起可以形成含氧的、可选融合环的药物可接受的盐或前药；但是，当R1和R4到R9是氢时，R2或R3不是3-甲氧基-4-苄氧基苯基或2-二甲基氨基乙氧甲基。用于制造治疗或预防阻断嘌呤受体，特别是腺苷受体，更特别是A2A受体可能有益的紊乱药物。所述紊乱是神经退行性紊乱或运动紊乱，包括帕金森病或进行性核上性麻痹、亨廷顿病、多系统萎缩、皮质基底节变性、威尔逊病、哈勒罗登-斯帕茨病、进行性苍白球萎缩、多巴响应性肌张力障碍、痉挛、阿尔茨海默病或其他导致运动障碍的基底节疾病。
• Cyclic hydroxamic acids as inhibitors of matrix metalloproteinases and/or TNF- &agr; converting enzyme (TACE)
  申请人：Bristol-Myers Squibb Company

  公开号：US06740649B2

  公开（公告）日：2004-05-25

  The present application describes novel cyclic hydroxamic acids of formula I: or pharmaceutically acceptable salt forms thereof, wherein ring B is a 5-7 membered cyclic system containing from 0-2 heteroatoms selected from O, N, NR1, and S(O)p, and 0-1 carbonyl groups and the other variables are defined in the present specification, which are useful as inhibitors of matrix metalloproteinases (MMP), TNF-&agr; converting enzyme (TACE), aggrecanase or a combination thereof, pharmaceutical compositions containing the same, and methods of using the same.

  本申请描述了新型环状羟肟酸的化学式I：或其药学上可接受的盐形式，其中环B是一个含有0-2个杂原子（选自O、N、NR1和S（O）p）和0-1个羰基的5-7成员环状系统，其它变量在本说明书中定义，该化合物可用作基质金属蛋白酶（MMP）、TNF-α转换酶（TACE）、Aggrecanase或其组合物的抑制剂，含有该化合物的制药组合物以及使用该化合物的方法。
• Spiro-cyclic &bgr;-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-&agr; converting enzyme (TACE)
  申请人：Bristol-Myers Squibb Pharma

  公开号：US06720329B2

  公开（公告）日：2004-04-13

  The present application describes novel spiro-cyclic &bgr;-amino acid derivatives of formula I: or pharmaceutically acceptable salt forms thereof, wherein ring B is a 3-13 membered carbocycle or heterocycle, ring C forms a 3-11 membered spiro-carbocycle or spiro-heterocycleon ring B, and the other variables are defined in the present specification, which are useful as as matrix metalloproteinases (MMP), TNF-&agr; converting enzyme (TACE), and/or aggrecanase inhibitors.

  本申请描述了新型螺环状&bgr;-氨基酸衍生物的公式I：或其药学上可接受的盐形式，其中环B是3-13成员的碳环或杂环，环C在环B上形成3-11成员的螺环状碳环或螺环状杂环，而其他变量在本说明书中定义，这些衍生物可用作基质金属蛋白酶（MMP）、TNF-&agr;转化酶（TACE）和/或聚集素酶抑制剂。